RT Journal
A1 GREEN WL, INGBAR SH
T1 DEcreased corticotropin reserve as isolated pituitary defect
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 1961
FD December 1
VO 108
IS 6
SP 945
OP 952
DO 10.1001/archinte.1961.03620120129018
UL http://dx.doi.org/10.1001/archinte.1961.03620120129018
AB Most patients with pituitary hypofunction have evidence of multiple target gland insufficiency arising from a destructive lesion in or near the sella turcica. Some patients with extensive pituitary destruction, however, exhibit hypogonadism as the only clinically evident defect; if the disease progresses, failure of thyroid and adrenal function later becomes apparent. Thus, it has been postulated and confirmed in animal experiments1 that a lesser degree of pituitary destruction is necessary to affect gonadal function than to affect the function of the thyroid gland and adrenal cortex.Investigation of the functional consequences of pituitary lesions in man, however, has been handicapped by the lack of procedures to test the pituitary's reserve capacity to secrete its several hormones. Recently, a delicate test of adrenocorticotrophic hormone (corticotropin; ACTH) reserve has been described, employing 1,2-bis-(3 pyridyl)-2-methyl-1-propanone (SU-4885), an inhibitor of adrenal 11-β-hydroxylase.2 This drug blocks the formation of the adrenal end-products, especially